`1201 NORTH MARKET STREET
`P.O. BOX 1347
`WILMINGTON, DELAWARE 19899-1347
`
`(302) 658-9200
`(302) 658-3989 FAX
`
`JACK B. BLUMENFELD
`(302) 351-9291
`jblumenfeld@mnat.com
`
`
`
`
`September 24, 2018
`
`
`The Honorable Richard G. Andrews
`United States District Court for the District of
`Delaware
`844 North King Street
`Wilmington, DE 19801
`
`HIGHLY CONFIDENTIAL –
`PROTECTIVE ORDER MATERIAL
`
`FILED UNDER SEAL
`
`Re:
`
`Bayer Intellectual Property GmbH v. Taro Pharmaceutical Industries, Ltd.
`C.A. No. 17-462 (RGA)
`
`
`
`Dear Judge Andrews:
`
`
`I write in response to Mylan’s September 21, 2018 letter, D.I. 121, submitted in response
`to Plaintiffs’ September 18 letter, D.I. 120, concerning the recent claim construction dispute that
`has arisen between the parties.
`
`Plaintiffs brought this dispute to the Court’s attention now to avoid a situation where the
`
`issue is first disclosed to the Court at trial, and sought guidance as to the Court’s preference
`concerning whether to further brief the issue now, or instead to address it at trial. In its response,
`Mylan asserts that additional claim construction briefing would be “a waste of the parties’ and
`the Court’s time and resources.” D.I. 121 at 1. However, Mylan then proceeds to present
`detailed arguments with citations to case law as to why its claim construction position is correct.
`
`Plaintiffs respectfully submit that either the parties should be permitted to brief the issue
`
`now, or it should be addressed at trial, whichever the Court prefers. Plaintiffs wish to point out,
`however, that Mylan’s arguments concerning the claim construction issue are misplaced.
`Contrary to Mylan’s
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`MYLAN - EXHIBIT 1068
`Mylan Pharmaceuticals Inc. v. Bayer Intellectual Property GmbH
`IPR2018-01143
`
`
`
`The Honorable Richard G. Andrews
`September 24, 2018
`Page 2
`
`
`
`
`
`
`
`
`
`Plaintiffs respectfully request the Court’s guidance on how to proceed. We are available
`
`to discuss this issue further at the Court’s convenience.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully,
`
`
`/s/ Jack B. Blumenfeld
`
`
`Jack B. Blumenfeld (#1014)
`
`
`JBB/bac
`
`cc:
`
`Clerk of the Court (via hand delivery)
`Counsel of Record Mylan Pharmaceuticals Inc. (via electronic mail)
`
`
`1 As the Court observed in its Markman opinion, Mylan never even responded to this argument
`in its claim construction briefing. D.I. 91 at 2 n.1.
`
`